@entity9229 ( @entity14137 ), a long-lasting @entity935 -agonist, specific for the D2 receptor, is effective in normalizing serum PRL levels in most @entity1 with @entity2013 or idiopathic @entity4089 . Because few data are presently available on the effects of @entity14137 treatment in @entity2013 , the aim of this open-label study was to investigate whether this drug was effective in producing @entity5 shrinkage, as well as in normalizing PRL levels. Twenty-three @entity1 with @entity2013 entered this study 15 @entity1 had had no treatment, whereas the remaining 8 @entity1 had been previously treated with @entity2847 , which was with-drawn because of intolerance. Three of 23 @entity1 had undergone unsuccessful surgery. Pretreatment serum PRL levels ranged from 100-3860 micrograms/L. @entity14137 was administered at a dose of 0.5-3 mg once or twice a week for 12-24 months. Magnetic resonance imaging (MRI) scans were performed before and 3, 6, 12, and 24 months after the beginning of treatment, to evaluate @entity5 shrinkage, defined as a decrease of at least 80% of baseline @entity5 volume. After 3-6 months of treatment with a low dose (0.5-1 mg/week), serum PRL levels normalized in 18 @entity1 . In the remaining 5 patients, whose serum PRL levels were not normalized, the dose was increased to 2-3 mg/week. This schedule caused the normalization of PRL levels in 1 @entity1 , whereas in the remaining 4 @entity1 , PRL levels were reduced to 30-82 micrograms/L. A @entity5 volume reduction greater than 80% at MRI occurred in 14 of 23 @entity1 (61%) after @entity14137 treatment (from 2609.4 +/- 534.7 to 530.1 +/- 141.3 mm3 at the 12-24th month follow-up, P < 0.001). A volume reduction of 41.8 +/- 3.4% was already evident after 3 months (1436 +/- 285.9 mm3; P < 0.001). The complete disappearance of the @entity5 mass at MRI occurred after 6 months of treatment with @entity14137 in 1 @entity1 , and in 5 @entity1 after 1 yr of treatment. An improvement of @entity227 was obtained in 9 of the 10 @entity1 presenting @entity227 before @entity14137 treatment. The drug was tolerated well by all @entity1 . Only 1 @entity1 experienced mild @entity390 , which disappeared spontaneously after the 2nd day of treatment. Long-term, a low dose of the D2 receptor agonist @entity14137 significantly reduced @entity5 volume and normalized serum PRL levels in a great majority of @entity1 bearing @entity2013 . This treatment met with excellent @entity1 compliance. This study suggests that @entity14137 can be used as a first choice drug treatment in @entity2013 , as already shown for @entity2013 and idiopathic @entity4089 .

Long-term and low-dose treatment with XXXX induces @entity2013 shrinkage.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['hyperprolactinemia'] @entity14137 :: ('MESH:C014396', 'Chemical') :: ['CAB'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['microprolactinomas', 'macroprolactinoma', 'microprolactinoma', 'macroprolactinomas'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairment', 'visual field defects'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['Cabergoline'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor']
@entity9229 :: (MESH:C047047,Chemical) :: ['cabergoline']
